Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Treatment with Fleeceflower Derivative Blocks Plaque Formation in Mouse Alzheimer's Disease Model

By BiotechDaily International staff writers
Posted on 26 Feb 2013
A compound derived from traditional Chinese herbal medicine prevented development of amyloid plaques when administered to young animals in a mouse model of Alzheimer's disease and reversed plaque formation when administered to older animals.

Investigators at the Capital Medical University (Beijing, China) worked with the APPV717I transgenic (Tg) mouse Alzheimer's disease model. In previous studies, these mice demonstrated cognitive impairments beginning at four months of age and developed amyloid plaques in the brain that were evident by 10 months.

In the current study Tg mice were treated with varying doses of tetrahydroxystilbene glucoside (TSG), the active compound derived from the Chinese herbal medicine tuber fleeceflower (Polygonum multiflorum Thunb). The drug was given to 4- or 10- month-old animals for a period of six months. At the end of the treatment, cDNA microarray analysis, reverse transcription PCR, western blotting, and immunochemical techniques were used to determine levels of alpha-synuclein messenger RNA (mRNA) and protein expression. Accumulation of alpha-synuclein leads to the formation of insoluble aggregates that have been implicated in several neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.

Results published in the January 2013 issue of the journal Restorative Neurology and Neuroscience revealed that alpha-synuclein mRNA expression increased in the hippocampus of four-month to 16-month old Tg mice compared with age-matched non-Tg controls. Alpha-synuclein protein expression in the hippocampus also increased significantly in four-month to 16-month old Tg mice. Significant down-regulation of alpha-synuclein mRNA and protein expression in the hippocampus was found after treatment with TSG for six months in both 10- and 16-month-old Tg mice. Production of dimers and tetramers of alpha-synuclein protein in Tg mice was inhibited after treatment with TSG.

The expression and aggregation of alpha-synuclein increased in an age-dependent fashion in Tg mice. TSG not only prevented over-expression of alpha-synuclein at an early stage, but also reversed the increased expression of alpha-synuclein and inhibited aggregation at the late stage of Tg mice. Therefore, TSG may have potential to prevent and treat Alzheimer's disease.

"Our results raise the possibility that TSG might be a novel compound for the treatment of Alzheimer's disease and dementia with Lewy body," said first author Dr. Lan Zhang, associate professor of pharmacology at Capital Medical University. "The role of alpha-synuclein, especially in the early phase of Alzheimer's disease, and its interaction with amyloid-beta should be considered when developing new therapeutic strategies to target Alzheimer's disease."

Related Links:

Capital Medical University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Blocking the activity of HSP101 may imprison the malaria parasite inside its protective vacuole within the red blood cell. In the electron micrograph, the malaria parasites appear in blue and uninfected red blood cells are shown in red (Photo courtesy of the [US] National Institute of Allergy and Infectious Diseases).

Heat Shock Protein Plays Critical Role in Malaria Parasite Protein Trafficking

A pair of recent papers described the molecular operators that enable the malaria parasite Plasmodium falciparum to export a large variety of proteins across the parasitophorous vacuolar membrane (PVM)... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: A one-year-old baby sits in a brain scanner, called magnetoencephalography (MEG)—a noninvasive approach to measuring brain activity. The baby listens to speech sounds such as “da” and “ta” played over headphones while researchers record her brain responses (Photo courtesy of the Institute for Learning & Brain Sciences at the University of Washington).

Brain Scanner Shows Infants’ Brains Rehearse Speech Sounds Months Before Their First Words

New research in 7- and 11-month-old infants revealed that speech sounds stimulate brain regions that coordinate and plan motor movements for speech. The new study suggests that babies’ brains begin establishing... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.